Related Experiment Videos
Double controlled comparison of IDU and trifluorothymidine in thirty-three patients with superficial herpetic
Abstract:
Thirty-three patients were followed in a double controlled study to test the efficacy of IDU and TFT on superficial epithelial herpes simplex virus infection. Sixteen received TFT and 17, IDU. There were four failures in patients on IDU therapy and no failures in the 16 patients using TFT. These results indicate a trend for greater efficacy of TFT than IDU. In those patients who healed with IDU and with TFT, there was no difference in the number of days to heal in each group.
Insights
Trifluridine (TFT) showed a trend toward greater efficacy than idoxuridine (IDU) in treating superficial epithelial herpes simplex virus infections. No treatment failures occurred with TFT, unlike with IDU.
Area of Science:
- Ophthalmology
- Virology
- Pharmacology
Background:
- Superficial epithelial herpes simplex virus infections can cause significant ocular morbidity.
- Topical antiviral therapies are crucial for managing these infections.
- Comparing the efficacy of different antiviral agents is essential for clinical practice.
Purpose of the Study:
- To compare the efficacy of trifluridine (TFT) and idoxuridine (IDU) in treating superficial epithelial herpes simplex virus infections.
- To evaluate the failure rates and healing times associated with each treatment.
Main Methods:
- A double-controlled study involving 33 patients with superficial epithelial herpes simplex virus infection.
- Patients were randomized to receive either TFT (16 patients) or IDU (17 patients).
- Outcomes assessed included treatment failure and time to heal.
Main Results:
- Four treatment failures were observed in the IDU group, while no failures occurred in the TFT group.
- A trend suggested greater efficacy for TFT compared to IDU.
- No significant difference in the number of days to heal was observed between the groups for patients who successfully healed.
Conclusions:
- Trifluridine (TFT) demonstrates a potential for superior efficacy over idoxuridine (IDU) in treating superficial epithelial herpes simplex virus infections.
- TFT may be a more effective therapeutic option due to its lack of treatment failures in this study.
- Further research may be warranted to confirm these findings and elucidate mechanisms of differential efficacy.